Hyper-Care CAIHL draft report

Hyper-Care: CAIHL reassessment

September 8, 2026. Published AI-assisted draft.

Hyper-Care describes patient-controlled record use, sponsor choice, study matching, and shared commercial value. These remain design claims. Key custody, revocation, compensation terms, and access without research participation are not independently established.

Scope and agency posture

Patient data collective and AI advocate design, including research matching and shared commercial value. Operational implementation remains unverified.

Posture: Potentially agency-expanding, with commercialization and disclosure caveats.

Axis: 78/100, retained provisionally. No numerical recalibration was performed.

Sources and documented findings

• The patient page describes AI interpretation, care-team sharing, study matching and compensation, with decisions said to remain under user control. https://hyper-care.org/patients-1

• The trust page claims patient-held keys, explicit opt-in data release, visible sponsors and revenue sharing. It names security frameworks but does not itself provide certification evidence or enforceable compensation terms. https://hyper-care.org/trust-1

Patient authority

Inference from the documented workflow: The described ability to select sponsors and control release is agency-relevant. Payment for contributing data does not itself establish governance rights or permission to refuse research while retaining care tools.

Critical capacity

Editorial assessment: Record explanation and study discovery could support informed action. No reviewed page establishes correction or appeal of an AI inference or an eligibility exclusion.

Informed control

Editorial assessment: Transparency promises are specific but remain promises. Encryption in transit and at rest does not alone establish that only the patient can decrypt data.

Assessment and limits

Keep the potential-design assessment with low-to-medium confidence. Remove the baseline's implication that missing verification mechanically lowers a number. Unverified controls limit confidence rather than proving poor agency.

Confidence: Low to moderate for design claims, low for operational guarantees.

Remaining uncertainty: Key custody, revocation enforcement, navigation without research participation and compensation terms remain unverified

Published documentation is evidence of stated conditions, not proof of actual implementation. Unknowns did not receive automatic negative points. Funding, sponsorship, and public code do not determine agency by themselves.

Review provenance

• Reviewer/model: OpenAI Codex / GPT-6.
• Method: Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.
• Human review: Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.
• Earlier review: 2026-06-30. Historical assessment. Earlier claims are not automatically reverified by this publication.